Shamburg News · 8-K/A filed Oct 9, 2026, 6:17 AM EDT

Company Announces Pre-Funded Warrant and Common Stock Private Placement Amendment

RNA · Atrium Therapeutics, Inc.

  • Financing
  • Other event
  • Materiality: medium

The company disclosed under Item 8.01 an amendment to its previously reported securities purchase agreement dated October 7, 2026, with accredited investors. The Offering covers 5,170,384 shares of common stock and pre-funded warrants to purchase up to 1,134,930 shares. Following the Offering, the company will have 21,571,507 shares of common stock outstanding, including shares issued on settlement of make-whole equity awards tied to its spin-off from Avidity Biosciences, Inc.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K/A, Item 8.01, accession 0001193125-26-418417.

Written from the filing by Shamburg Markets. Figures are as reported by the company.